Current Report Filing (8-k)
January 09 2017 - 9:28AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): January 9, 2017
Marina
Biotech, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-13789
|
|
11-2658569
|
(State
or other jurisdiction
|
|
(Commission
|
|
(I.R.S.
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
|
|
|
|
|
17870
Castleton Street, Suite 250
City of Industry, CA
|
|
|
|
91748
|
Address
of principal executive offices)
|
|
|
|
(Zip
Code)
|
|
|
|
|
|
Registrant’s
telephone number, including area code:
|
|
425-892-4322
|
N/A
Former
name or former address, if changed since last report
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
8.01 Other Events.
On
Monday, January 9, 2017, Marina Biotech, Inc. (the “Company”) will present clinical data from its CEQ508 phase 1 trial
for the treatment of Familial Adenomatous Polyposis (FAP) at its previously announced presentation at the 9
th
Annual
Biotech Showcase. The trial has met its primary and secondary endpoints of safety and efficacy for CEQ508. As detailed in the
presentation, the data demonstrated “safety and statistically significant Catenin Knockdown for Cohort 2 along the Duodenum
and Ileum.” Management will also state during the presentation its intentions to continue clinical development of CEQ508
in combination with IT-102, which was acquired in the recent merger with IthenaPharma. A copy of the slide deck used in connection
with the presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Presentation
of Marina Biotech, Inc. at the 9
th
Annual Biotech Showcase on January 9, 2017.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
|
Marina Biotech, Inc
|
|
|
|
January
9, 2017
|
By:
|
/s/
Joseph W. Ramelli
|
|
Name:
|
Joseph
W. Ramelli
|
|
Title:
|
CEO
|
EXHIBIT
INDEX
Exhibit
No.
|
|
Description
|
|
|
|
99.1
|
|
Presentation
of Marina Biotech, Inc. at the 9
th
Annual Biotech Showcase on January 9, 2017.
|